Baidu
map

抗粉刺类护肤品在痤疮中的应用指南

2019-10-30 中国皮肤性病相关专家小组(统称) 中国皮肤性病学杂志.2019.33(10):1107-1109.

痤疮( acne vulgaris) 是一种毛囊皮脂腺的慢性炎症性皮肤病,好发于面部、前胸、后背等皮脂溢出部位,已成为全球患病率排名第八的疾病,严重影响患者的容貌及身心健康。抗粉刺类护肤品在痤疮防治中的作用越来越显现,已成为单一或与药物、物理、化学联合防治痤疮的重要手段[2-3]。为指导临床医师合理选择抗粉刺类护肤品,现组织国内相关专家,依据痤疮的基础研究和临床证据及国内外痤疮治疗指南,特制定本指

中文标题:

抗粉刺类护肤品在痤疮中的应用指南

发布日期:

2019-10-30

简要介绍:

痤疮( acne vulgaris) 是一种毛囊皮脂腺的慢性炎症性皮肤病,好发于面部、前胸、后背等皮脂溢出部位,已成为全球患病率排名第八的疾病,严重影响患者的容貌及身心健康。抗粉刺类护肤品在痤疮防治中的作用越来越显现,已成为单一或与药物、物理、化学联合防治痤疮的重要手段[2-3]。为指导临床医师合理选择抗粉刺类护肤品,现组织国内相关专家,依据痤疮的基础研究和临床证据及国内外痤疮治疗指南,特制定本指南。

 

拓展指南:痤疮相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=抗粉刺类护肤品在痤疮中的应用指南)] GetToolGuiderByIdResponse(projectId=1, id=8d7bd1c00181119e, title=抗粉刺类护肤品在痤疮中的应用指南, enTitle=, guiderFrom=中国皮肤性病学杂志.2019.33(10):1107-1109., authorId=null, author=, summary=痤疮( acne vulgaris) 是一种毛囊皮脂腺的慢性炎症性皮肤病,好发于面部、前胸、后背等皮脂溢出部位,已成为全球患病率排名第八的疾病,严重影响患者的容貌及身心健康。抗粉刺类护肤品在痤疮防治中的作用越来越显现,已成为单一或与药物、物理、化学联合防治痤疮的重要手段[2-3]。为指导临床医师合理选择抗粉刺类护肤品,现组织国内相关专家,依据痤疮的基础研究和临床证据及国内外痤疮治疗指南,特制定本指, cover=, journalId=null, articlesId=null, associationId=939, associationName=中国皮肤性病相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Wed Oct 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>痤疮( acne vulgaris) 是一种毛囊皮脂腺的慢性炎症性皮肤病,好发于面部、前胸、后背等皮脂溢出部位,已成为全球患病率排名第八的疾病,严重影响患者的容貌及身心健康。抗粉刺类护肤品在痤疮防治中的作用越来越显现,已成为单一或与药物、物理、化学联合防治痤疮的重要手段[2-3]。为指导临床医师合理选择抗粉刺类护肤品,现组织国内相关专家,依据痤疮的基础研究和临床证据及国内外痤疮治疗指南,特制定本指南。 </P> <P> </P>拓展指南:<strong>与<font color=red>痤疮</font>相关指南:</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=9b3601c001e98812" title="中国痤疮治疗指南(2019修订版)" target=_blank>中国痤疮治疗指南(2019修订版)</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=33cff1c00159568a" title="2017 JDA指南:寻常痤疮的治疗" target=_blank>2017 JDA指南:寻常痤疮的治疗</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=492f71c001a98119" title="痤疮(粉刺)中医治疗专家共识" target=_blank>痤疮(粉刺)中医治疗专家共识</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=0d1661c001a8095d" title="中国玫瑰痤疮诊疗专家共识(2016)" target=_blank>中国玫瑰痤疮诊疗专家共识(2016)</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=a7cf31c001a5e0fa" title="2017 循证建议:暴发性痤疮及其变种的管理" target=_blank>2017 循证建议:暴发性痤疮及其变种的管理</a></li> 更多信息请点击:<a href="//m.capotfarm.com/guideline/list.do?q=%E7%97%A4%E7%96%AE" target=_blank>有关痤疮更多指南</a></ul>, tagList=[TagDto(tagId=96113, tagName=抗粉刺类护肤品), TagDto(tagId=16414, tagName=痤疮)], categoryList=[CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4884, appHits=334, showAppHits=0, pcHits=2488, showPcHits=3240, likes=50, shares=14, comments=22, approvalStatus=1, publishedTime=Wed Oct 30 00:30:15 CST 2019, publishedTimeString=2019-10-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Oct 30 00:30:15 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 06:17:58 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=抗粉刺类护肤品在痤疮中的应用指南)])
抗粉刺类护肤品在痤疮中的应用指南
下载请点击:
评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1238428, encodeId=23a21238428a2, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a898273581, createdName=ms5000000074404690, createdTime=Sat Aug 13 09:50:16 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199455, encodeId=37231199455a0, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff66523836, createdName=ms6000002123920736, createdTime=Fri Mar 04 19:30:41 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199454, encodeId=ef1611994546e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff66523836, createdName=ms6000002123920736, createdTime=Fri Mar 04 19:30:21 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069242, encodeId=0ff21069242b0, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d475704909, createdName=ms1000001132029860, createdTime=Thu Nov 11 12:00:45 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057948, encodeId=1f9f105e94847, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211005/9ffaaa67335e411baa7fa1f1ae688953/deaa3ee0ce6345cf8e7455ff5b4a9a69.jpg, createdBy=0cf65078066, createdName=145a8e01m54暂无昵称, createdTime=Tue Oct 05 20:55:12 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
    2022-08-13 ms5000000074404690

    很好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1238428, encodeId=23a21238428a2, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a898273581, createdName=ms5000000074404690, createdTime=Sat Aug 13 09:50:16 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199455, encodeId=37231199455a0, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff66523836, createdName=ms6000002123920736, createdTime=Fri Mar 04 19:30:41 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199454, encodeId=ef1611994546e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff66523836, createdName=ms6000002123920736, createdTime=Fri Mar 04 19:30:21 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069242, encodeId=0ff21069242b0, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d475704909, createdName=ms1000001132029860, createdTime=Thu Nov 11 12:00:45 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057948, encodeId=1f9f105e94847, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211005/9ffaaa67335e411baa7fa1f1ae688953/deaa3ee0ce6345cf8e7455ff5b4a9a69.jpg, createdBy=0cf65078066, createdName=145a8e01m54暂无昵称, createdTime=Tue Oct 05 20:55:12 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
    2022-03-04 ms6000002123920736

    很不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1238428, encodeId=23a21238428a2, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a898273581, createdName=ms5000000074404690, createdTime=Sat Aug 13 09:50:16 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199455, encodeId=37231199455a0, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff66523836, createdName=ms6000002123920736, createdTime=Fri Mar 04 19:30:41 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199454, encodeId=ef1611994546e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff66523836, createdName=ms6000002123920736, createdTime=Fri Mar 04 19:30:21 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069242, encodeId=0ff21069242b0, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d475704909, createdName=ms1000001132029860, createdTime=Thu Nov 11 12:00:45 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057948, encodeId=1f9f105e94847, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211005/9ffaaa67335e411baa7fa1f1ae688953/deaa3ee0ce6345cf8e7455ff5b4a9a69.jpg, createdBy=0cf65078066, createdName=145a8e01m54暂无昵称, createdTime=Tue Oct 05 20:55:12 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
    2022-03-04 ms6000002123920736

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1238428, encodeId=23a21238428a2, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a898273581, createdName=ms5000000074404690, createdTime=Sat Aug 13 09:50:16 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199455, encodeId=37231199455a0, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff66523836, createdName=ms6000002123920736, createdTime=Fri Mar 04 19:30:41 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199454, encodeId=ef1611994546e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff66523836, createdName=ms6000002123920736, createdTime=Fri Mar 04 19:30:21 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069242, encodeId=0ff21069242b0, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d475704909, createdName=ms1000001132029860, createdTime=Thu Nov 11 12:00:45 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057948, encodeId=1f9f105e94847, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211005/9ffaaa67335e411baa7fa1f1ae688953/deaa3ee0ce6345cf8e7455ff5b4a9a69.jpg, createdBy=0cf65078066, createdName=145a8e01m54暂无昵称, createdTime=Tue Oct 05 20:55:12 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
    2021-11-11 ms1000001132029860

    不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1238428, encodeId=23a21238428a2, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a898273581, createdName=ms5000000074404690, createdTime=Sat Aug 13 09:50:16 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199455, encodeId=37231199455a0, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff66523836, createdName=ms6000002123920736, createdTime=Fri Mar 04 19:30:41 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199454, encodeId=ef1611994546e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ff66523836, createdName=ms6000002123920736, createdTime=Fri Mar 04 19:30:21 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069242, encodeId=0ff21069242b0, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d475704909, createdName=ms1000001132029860, createdTime=Thu Nov 11 12:00:45 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057948, encodeId=1f9f105e94847, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211005/9ffaaa67335e411baa7fa1f1ae688953/deaa3ee0ce6345cf8e7455ff5b4a9a69.jpg, createdBy=0cf65078066, createdName=145a8e01m54暂无昵称, createdTime=Tue Oct 05 20:55:12 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
    2021-10-05 145a8e01m54暂无昵称

    不错

    0

Baidu
map
Baidu
map
Baidu
map